Obio Technology (Shanghai) Corp., Ltd. (SHA:688238)

Market Cap	4.96B
Revenue (ttm)	254.94M
Net Income (ttm)	-313.04M
Shares Out	630.31M
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,170,491
Average Volume	18,861,354
Open	7.63
Previous Close	7.62
Day's Range	7.59 - 7.80
52-Week Range	4.16 - 9.20
Beta	0.61
RSI	49.86
Earnings Date	Oct 23, 2025

About SHA:688238

Obio Technology (Shanghai) Corp., Ltd., a biotechnology company, focuses on the development of gene therapy vectors in China. The company provides gene function and gene therapy research, and other CRO services, such as drug target and drug efficacy research. It also offers CDMO services, such as process development and testing, IND-CMC pharmaceutical research, and clinical sample GMP production for the research and development of genetic drugs. The company was founded in 2013 and is headquartered in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 692
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688238

Financial Performance

In 2024, SHA:688238's revenue was 248.15 million, an increase of 21.16% compared to the previous year's 204.81 million. Losses were -321.81 million, 151.5% more than in 2023.